Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$0.96 USD
-0.06 (-6.23%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $0.95 -0.01 (-0.68%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Brokerage Reports
Karyopharm Therapeutics Inc. [KPTI]
Reports for Purchase
Showing records 381 - 387 ( 387 total )
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Selinexor Update in NHL and MM Shows High Response Rates Maintained, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov 17
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Q3:14 Earnings, KPTI Continuing to Aggressively Pursue Clinical Development of Selinexor, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov 10
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Initiating Coverage with an OUTPERFORM Rating and $50 Price Target, Novel Broad-Spectrum Anti-Tumor Inhibition of Nuclear Export
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D